familial Alzheimer disease

Summary

familial Alzheimer disease (MONDO:0100087) is a disease and 4 clinical trials. Top therapeutic interventions include bromocriptine mesylate. A subtype of Alzheimer disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	familial Alzheimer disease
Mondo ID	MONDO:0100087
UMLS	C0276496
MedGen	82914
Is cancer (heuristic)	no

Also known as: Alzheimer disease, familial · FAD · GARD:0000632

Disease family

This is a subtype of Alzheimer disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › dementia › Alzheimer disease › familial Alzheimer disease

Related subtypes (4): Alzheimer disease 16, Alzheimer disease 17, Alzheimer disease 18, Alzheimer disease 19

Subtypes (2): Alzheimer disease 2, early-onset autosomal dominant Alzheimer disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04413344	PHASE1/PHASE2	COMPLETED	Repurposing Bromocriptine for Abeta Metabolism in Alzheimer’s Disease
NCT03653156	Not specified	RECRUITING	China Cognition and Aging Study
NCT03657732	Not specified	RECRUITING	The Chinese Familial Alzheimer’s Network
NCT03884647	Not specified	COMPLETED	DELPHI in Subjects at Risk for Stroke and Dementia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BROMOCRIPTINE MESYLATE	4	1